NCT06419205Phase 2Recruiting

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Study sponsor: Akebia Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02Estimated
Enrollment · participants30Estimated
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events (AEs) to evaluate the safety of ADX-097. After: Measure: Number of participants reporting treatment emergent adverse events (TEAEs).

Participant count type changed

Before: Actual. After: Estimated.

Enrollment · participant count changed

Before: 0 participants (actual). After: 30 participants (planned).

Primary completion date changed

Before: Jun 2026. After: Feb 2028.

Recruitment status changed

Before: Withdrawn. After: Not yet recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview